Ventripoint Diagnostics Ltd. Stock OTC Markets

Equities

VPTDF

CA92281P2008

Advanced Medical Equipment & Technology

Market Closed - OTC Markets 15:56:56 2024-07-16 EDT 5-day change 1st Jan Change
0.1555 USD -2.81% Intraday chart for Ventripoint Diagnostics Ltd. -1.14% -31.86%
Sales 2022 68.17K 49.82K Sales 2023 49.18K 35.95K Capitalization 46.26M 33.81M
Net income 2022 -4M -2.92M Net income 2023 -4M -2.92M EV / Sales 2022 552 x
Net cash position 2022 4.73M 3.45M Net cash position 2023 882K 645K EV / Sales 2023 923 x
P/E ratio 2022
-8.64 x
P/E ratio 2023
-9.5 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 97.84%
More Fundamentals * Assessed data
Dynamic Chart
Ventripoint Diagnostics Ltd. Appoints Matt Dobson as Marketing Director CI
Ventripoint Diagnostics Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Ventripoint Diagnostics Ltd. Submits Next Generation of Software, VMS+4.0, to the U.S. Food and Drug Administration CI
Duke University Health Center Purchases Ventripoint's AI Heart-Scan Technology CI
Ventripoint Diagnostics Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
VentriPoint Diagnostics Ltd. announced that it expects to receive CAD 3 million in funding CI
Ventripoint Diagnostics Ltd. Releases Significant Upgrade to the Design and Function of Its Whole-Heart Analysis System (VMS+3.2) CI
Ventripoint Diagnostics Ltd. Showcases A.I. Powered Heart-Scanning Technology at International Cardiology Conferences CI
Ventripoint Diagnostics Ltd. Appoints Hugh Macnaught as Interim CEO CI
Ventripoint Diagnostics Ltd. Appoints Hugh Macnaught as President CI
The Paediatric Heart Centre At the Medical University of Vienna Has Chosen to Adopt the Vms+ as Its Cardiac Diagnostic Tool CI
VentriPoint Diagnostics Ltd. Announces Appointment of Dr. Luc Mertens to Clinical Advisory Board CI
VentriPoint Diagnostics Ltd. Enters into A Global Distribution and Marketing Agreement with Ascend Cardiovascular CI
VentriPoint Diagnostics Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
VentriPoint Diagnostics Ltd. Announces Executive Changes CI
More news
1 day-2.81%
1 week-1.14%
Current month+0.91%
1 month+8.36%
3 months-3.66%
6 months-35.69%
Current year-31.86%
More quotes
1 week
0.15
Extreme 0.15
0.16
1 month
0.14
Extreme 0.1361
0.21
Current year
0.14
Extreme 0.1361
0.27
1 year
0.10
Extreme 0.0982
0.27
3 years
0.06
Extreme 0.06
0.51
5 years
0.00
Extreme 0.0001
0.55
10 years
0.00
Extreme 0.0001
0.66
More quotes
Managers TitleAgeSince
Chief Executive Officer - 02-04
Chairman 76 10-09-30
Members of the board TitleAgeSince
Director/Board Member - 19-12-16
Director/Board Member - 21-12-19
Chairman 76 10-09-30
More insiders
Date Price Change Volume
24-07-16 0.1555 -2.81% 71 005
24-07-15 0.16 +0.57% 961
24-07-12 0.1591 +0.06% 700
24-07-11 0.159 -0.06% 534
24-07-10 0.1591 +1.14% 43,655

Delayed Quote OTC Markets, July 16, 2024 at 03:56 pm

More quotes
Ventripoint Diagnostics Ltd is a Canada-based medical device company. The Company is engaged in the development and commercialization of diagnostic tools that monitor patients with heart disease. It is developing a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, imaging, and cardiotoxicity in oncology patients. The Company’s Ventripoint Medical System (VMS+) is a diagnostic aid that was developed to provide a point-of-care solution to better communicate the heart’s structure and function without the need for magnetic resonance imaging (MRI). VMS+ enhances ultrasound, providing three-dimensional (3D) technology that allows for visualization of all four chambers of the heart. The system’s proprietary Knowledge Based Reconstruction (KBR) technology creates 3D models of the heart and calculates volumes and ejection fractions equivalent to the gold-standard Magnetic resonance imaging (MRI).
More about the company